Loading…

Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry

Midazolam (MDZ), a short‐acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensi...

Full description

Saved in:
Bibliographic Details
Published in:Rapid communications in mass spectrometry 2007-01, Vol.21 (9), p.1531-1540
Main Authors: Link, Bettina, Haschke, Manuel, Wenk, Markus, Krähenbühl, Stephan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53
cites cdi_FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53
container_end_page 1540
container_issue 9
container_start_page 1531
container_title Rapid communications in mass spectrometry
container_volume 21
creator Link, Bettina
Haschke, Manuel
Wenk, Markus
Krähenbühl, Stephan
description Midazolam (MDZ), a short‐acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantitative determination of MDZ and two of its metabolites (1′‐hydroxymidazolam (1′‐OHMDZ) and 4‐hydroxymidazolam (4‐OHMDZ)) in human plasma and oral fluid. After liquid‐liquid extraction with hexane/dichloromethane (73:27, v/v), the analytes were separated on a Luna C18(2) (100 × 2.1 mm) analytical column using gradient elution. Detection was achieved using tandem mass spectrometry on an ion trap mass spectrometer. Midazolam‐d6 was used as internal standard for quantification. The calibration curves were linear (R2 >0.998) between 0.05 and 20 ng/mL for MDZ and both metabolites in both matrices. Using 1 mL samples, the limit of detection was 0.025 ng/mL and the limit of quantification was 0.05 ng/mL for MDZ and the hydroxy metabolites in both matrices. Intra‐ and inter‐day accuracies, determined at three different concentrations, were between 92.1 and 102.3% and the corresponding coefficients of variation were
doi_str_mv 10.1002/rcm.2987
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70392362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70392362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53</originalsourceid><addsrcrecordid>eNp10ctu1DAYBWALgejQIvEEyCvEJq1viSdLNIWC1Jaq4iY21p_EYQx2nNqOaPpEPCaeTlRWLCx78ekcWQehF5QcU0LYSWjdMavX8hFaUVLLgjBOH6MVqUtaCFqvD9CzGH8SQmnJyFN0QKWgpCLlCv051UkHZwZIxg_Y99iZDu68BYdh6LBJEW_nLvjbGTudoPHWJB2xGfB2cjDg0UJ0cG99AIt7O5kONzO25mb3arfBO0j-R4BxO59oq9sUfBwDzDg3mrt98e6kTHDKSdphBzHiON7j3BvmI_SkBxv18-U-RJ_fvf20eV-cfzz7sHlzXrSCcVmUlFZarAUQKDWvadWzjoiGU1kJ3TZ9TQUVjK4rYAIqTroqu6YWvO8EL9uSH6JX-9wx-JtJx6Scia22Fgbtp6gk4TXjFcvw9R62-Tsx6F6NwTgIs6JE7VZReRW1WyXTl0vm1Djd_YPLDBkUe_DbWD3_N0hdby6WwMWbmPTtg4fwS1WSy1J9vTxT4tv1lwv5vVZX_C-zFanN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70392362</pqid></control><display><type>article</type><title>Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Link, Bettina ; Haschke, Manuel ; Wenk, Markus ; Krähenbühl, Stephan</creator><creatorcontrib>Link, Bettina ; Haschke, Manuel ; Wenk, Markus ; Krähenbühl, Stephan</creatorcontrib><description>Midazolam (MDZ), a short‐acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantitative determination of MDZ and two of its metabolites (1′‐hydroxymidazolam (1′‐OHMDZ) and 4‐hydroxymidazolam (4‐OHMDZ)) in human plasma and oral fluid. After liquid‐liquid extraction with hexane/dichloromethane (73:27, v/v), the analytes were separated on a Luna C18(2) (100 × 2.1 mm) analytical column using gradient elution. Detection was achieved using tandem mass spectrometry on an ion trap mass spectrometer. Midazolam‐d6 was used as internal standard for quantification. The calibration curves were linear (R2 &gt;0.998) between 0.05 and 20 ng/mL for MDZ and both metabolites in both matrices. Using 1 mL samples, the limit of detection was 0.025 ng/mL and the limit of quantification was 0.05 ng/mL for MDZ and the hydroxy metabolites in both matrices. Intra‐ and inter‐day accuracies, determined at three different concentrations, were between 92.1 and 102.3% and the corresponding coefficients of variation were &lt;7.3%. The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1′‐OHMDZ and 4‐OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'‐OHMDZ and 4‐OHMDZ, respectively, in oral fluid. The method was successfully applied to a pharmacokinetic study, showing that MDZ and its hydroxy metabolites can be determined precisely in in vivo samples obtained following a single oral or intravenous dose of 2 mg MDZ. The method appears to be useful for CYP3A phenotyping in plasma using sub‐therapeutic MDZ doses, but larger studies are needed to test this assumption. Copyright © 2007 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0951-4198</identifier><identifier>EISSN: 1097-0231</identifier><identifier>DOI: 10.1002/rcm.2987</identifier><identifier>PMID: 17410605</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Chromatography, High Pressure Liquid - methods ; Humans ; Hypnotics and Sedatives - blood ; Hypnotics and Sedatives - pharmacokinetics ; Midazolam - analogs &amp; derivatives ; Midazolam - blood ; Midazolam - pharmacokinetics ; Reproducibility of Results ; Saliva - chemistry ; Spectrometry, Mass, Electrospray Ionization - methods ; Tandem Mass Spectrometry - methods</subject><ispartof>Rapid communications in mass spectrometry, 2007-01, Vol.21 (9), p.1531-1540</ispartof><rights>Copyright © 2007 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright 2007 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53</citedby><cites>FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17410605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Link, Bettina</creatorcontrib><creatorcontrib>Haschke, Manuel</creatorcontrib><creatorcontrib>Wenk, Markus</creatorcontrib><creatorcontrib>Krähenbühl, Stephan</creatorcontrib><title>Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry</title><title>Rapid communications in mass spectrometry</title><addtitle>Rapid Commun. Mass Spectrom</addtitle><description>Midazolam (MDZ), a short‐acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantitative determination of MDZ and two of its metabolites (1′‐hydroxymidazolam (1′‐OHMDZ) and 4‐hydroxymidazolam (4‐OHMDZ)) in human plasma and oral fluid. After liquid‐liquid extraction with hexane/dichloromethane (73:27, v/v), the analytes were separated on a Luna C18(2) (100 × 2.1 mm) analytical column using gradient elution. Detection was achieved using tandem mass spectrometry on an ion trap mass spectrometer. Midazolam‐d6 was used as internal standard for quantification. The calibration curves were linear (R2 &gt;0.998) between 0.05 and 20 ng/mL for MDZ and both metabolites in both matrices. Using 1 mL samples, the limit of detection was 0.025 ng/mL and the limit of quantification was 0.05 ng/mL for MDZ and the hydroxy metabolites in both matrices. Intra‐ and inter‐day accuracies, determined at three different concentrations, were between 92.1 and 102.3% and the corresponding coefficients of variation were &lt;7.3%. The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1′‐OHMDZ and 4‐OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'‐OHMDZ and 4‐OHMDZ, respectively, in oral fluid. The method was successfully applied to a pharmacokinetic study, showing that MDZ and its hydroxy metabolites can be determined precisely in in vivo samples obtained following a single oral or intravenous dose of 2 mg MDZ. The method appears to be useful for CYP3A phenotyping in plasma using sub‐therapeutic MDZ doses, but larger studies are needed to test this assumption. Copyright © 2007 John Wiley &amp; Sons, Ltd.</description><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Humans</subject><subject>Hypnotics and Sedatives - blood</subject><subject>Hypnotics and Sedatives - pharmacokinetics</subject><subject>Midazolam - analogs &amp; derivatives</subject><subject>Midazolam - blood</subject><subject>Midazolam - pharmacokinetics</subject><subject>Reproducibility of Results</subject><subject>Saliva - chemistry</subject><subject>Spectrometry, Mass, Electrospray Ionization - methods</subject><subject>Tandem Mass Spectrometry - methods</subject><issn>0951-4198</issn><issn>1097-0231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNp10ctu1DAYBWALgejQIvEEyCvEJq1viSdLNIWC1Jaq4iY21p_EYQx2nNqOaPpEPCaeTlRWLCx78ekcWQehF5QcU0LYSWjdMavX8hFaUVLLgjBOH6MVqUtaCFqvD9CzGH8SQmnJyFN0QKWgpCLlCv051UkHZwZIxg_Y99iZDu68BYdh6LBJEW_nLvjbGTudoPHWJB2xGfB2cjDg0UJ0cG99AIt7O5kONzO25mb3arfBO0j-R4BxO59oq9sUfBwDzDg3mrt98e6kTHDKSdphBzHiON7j3BvmI_SkBxv18-U-RJ_fvf20eV-cfzz7sHlzXrSCcVmUlFZarAUQKDWvadWzjoiGU1kJ3TZ9TQUVjK4rYAIqTroqu6YWvO8EL9uSH6JX-9wx-JtJx6Scia22Fgbtp6gk4TXjFcvw9R62-Tsx6F6NwTgIs6JE7VZReRW1WyXTl0vm1Djd_YPLDBkUe_DbWD3_N0hdby6WwMWbmPTtg4fwS1WSy1J9vTxT4tv1lwv5vVZX_C-zFanN</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Link, Bettina</creator><creator>Haschke, Manuel</creator><creator>Wenk, Markus</creator><creator>Krähenbühl, Stephan</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry</title><author>Link, Bettina ; Haschke, Manuel ; Wenk, Markus ; Krähenbühl, Stephan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Humans</topic><topic>Hypnotics and Sedatives - blood</topic><topic>Hypnotics and Sedatives - pharmacokinetics</topic><topic>Midazolam - analogs &amp; derivatives</topic><topic>Midazolam - blood</topic><topic>Midazolam - pharmacokinetics</topic><topic>Reproducibility of Results</topic><topic>Saliva - chemistry</topic><topic>Spectrometry, Mass, Electrospray Ionization - methods</topic><topic>Tandem Mass Spectrometry - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Link, Bettina</creatorcontrib><creatorcontrib>Haschke, Manuel</creatorcontrib><creatorcontrib>Wenk, Markus</creatorcontrib><creatorcontrib>Krähenbühl, Stephan</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rapid communications in mass spectrometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Link, Bettina</au><au>Haschke, Manuel</au><au>Wenk, Markus</au><au>Krähenbühl, Stephan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry</atitle><jtitle>Rapid communications in mass spectrometry</jtitle><addtitle>Rapid Commun. Mass Spectrom</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>21</volume><issue>9</issue><spage>1531</spage><epage>1540</epage><pages>1531-1540</pages><issn>0951-4198</issn><eissn>1097-0231</eissn><abstract>Midazolam (MDZ), a short‐acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantitative determination of MDZ and two of its metabolites (1′‐hydroxymidazolam (1′‐OHMDZ) and 4‐hydroxymidazolam (4‐OHMDZ)) in human plasma and oral fluid. After liquid‐liquid extraction with hexane/dichloromethane (73:27, v/v), the analytes were separated on a Luna C18(2) (100 × 2.1 mm) analytical column using gradient elution. Detection was achieved using tandem mass spectrometry on an ion trap mass spectrometer. Midazolam‐d6 was used as internal standard for quantification. The calibration curves were linear (R2 &gt;0.998) between 0.05 and 20 ng/mL for MDZ and both metabolites in both matrices. Using 1 mL samples, the limit of detection was 0.025 ng/mL and the limit of quantification was 0.05 ng/mL for MDZ and the hydroxy metabolites in both matrices. Intra‐ and inter‐day accuracies, determined at three different concentrations, were between 92.1 and 102.3% and the corresponding coefficients of variation were &lt;7.3%. The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1′‐OHMDZ and 4‐OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'‐OHMDZ and 4‐OHMDZ, respectively, in oral fluid. The method was successfully applied to a pharmacokinetic study, showing that MDZ and its hydroxy metabolites can be determined precisely in in vivo samples obtained following a single oral or intravenous dose of 2 mg MDZ. The method appears to be useful for CYP3A phenotyping in plasma using sub‐therapeutic MDZ doses, but larger studies are needed to test this assumption. Copyright © 2007 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>17410605</pmid><doi>10.1002/rcm.2987</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0951-4198
ispartof Rapid communications in mass spectrometry, 2007-01, Vol.21 (9), p.1531-1540
issn 0951-4198
1097-0231
language eng
recordid cdi_proquest_miscellaneous_70392362
source Wiley-Blackwell Read & Publish Collection
subjects Chromatography, High Pressure Liquid - methods
Humans
Hypnotics and Sedatives - blood
Hypnotics and Sedatives - pharmacokinetics
Midazolam - analogs & derivatives
Midazolam - blood
Midazolam - pharmacokinetics
Reproducibility of Results
Saliva - chemistry
Spectrometry, Mass, Electrospray Ionization - methods
Tandem Mass Spectrometry - methods
title Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A48%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20midazolam%20and%20its%20hydroxy%20metabolites%20in%20human%20plasma%20and%20oral%20fluid%20by%20liquid%20chromatography/electrospray%20ionization%20ion%20trap%20tandem%20mass%20spectrometry&rft.jtitle=Rapid%20communications%20in%20mass%20spectrometry&rft.au=Link,%20Bettina&rft.date=2007-01-01&rft.volume=21&rft.issue=9&rft.spage=1531&rft.epage=1540&rft.pages=1531-1540&rft.issn=0951-4198&rft.eissn=1097-0231&rft_id=info:doi/10.1002/rcm.2987&rft_dat=%3Cproquest_cross%3E70392362%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4237-5116e484a0a5e3916f2d04b31764ecbf914142186a24a630d6a5eb943fd435c53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70392362&rft_id=info:pmid/17410605&rfr_iscdi=true